Project Grant K99CA304508
Award Date
7/17/25
Completion Date
6/30/27
Dollars Obligated
$123K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $510,431 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Johns Hopkins University. The grant, effective July 1, 2025 through June 30, 2030, supports comprehensive research to investigate the fundamental biological mechanisms underlying tumor dormancy, metastatic recurrence, and therapeutic resistance in aging melanoma patients. The research aims to uncover how the aging immune microenvironment influences tumor cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690 to Health Research, Inc. at Roswell Park Comprehensive Cancer Center to decipher the molecular mechanisms underlying breast cancer bone metastasis. The overarching goals are to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases, and to identify new therapeutic targets to treat both early and advanced...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will support a $734,942 research project over 5 years from August 2025 to July 2030. The research aims to evaluate how biological aging metrics, such as epigenetic clocks and leukocyte composition, are associated with cardiovascular disease (CVD) and mortality risk in breast cancer survivors. The project will...
The federal Project Grant award R01CA289387, totaling $657,121.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to develop a novel dendritic cell therapy for treating leptomeningeal disease (LMD), a severe complication that occurs in 5% of advanced-stage breast cancer patients. The research aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. at Roswell Park in Buffalo, NY to conduct research on the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The key objectives are to investigate the bifunctional mechanisms of the PFKFB4 enzyme in regulating metabolic and genetic plasticity in the TNBC tumor microenvironment, and to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $204,474 to The Regents of the University of Colorado to conduct research aimed at defining the relationship between cell quiescence and senescence. The project will use advanced microscopy techniques and RNA sequencing to study the molecular mechanisms that mediate the transition from a reversible quiescent state to permanent cell cycle arrest, or senescence. The research...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
The National Cancer Institute (NCI) awarded a $549,962 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant, awarded from April 1, 2025 to March 31, 2030, will fund a research project to determine how antibodies and cellular ligands regulate the immunosuppressive function of the lymphocyte-activation gene 3 (LAG3) protein. The project aims to provide fundamental insights into...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340 to the University of Miami to support research aimed at identifying epigenetic vulnerabilities in endocrine-resistant breast cancer. The project will investigate the role of the CoREST-SWI/SNF axis in regulating breast cancer cell plasticity and endocrine therapy resistance, focusing on two key resistant settings: breast cancers with ESR1 mutations and those with ARID1A...
This $369,868 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the functional role of mitochondrial transfer from nerves to breast cancer cells, and how this process impacts cancer metastasis and the generation of cancer stem cells. The project aims to use innovative lineage-tracing techniques to quantify the contribution of nerve-to-cancer mitochondrial transfer to the breast cancer metastasis cascade, and evaluate...